The emerging role of epigenetics in urological cancers.

Kavitha Ramachandran, Mark S. Soloway, Rakesh Singal, Murugesan Manoharan

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

DNA methylation and histone modifications constitute the common epigenetic modifications in vertebrate genomes. The epigenetic changes are early event in the cancer development and are reversible. Over the last decade, the field of epigenetics has made considerable progress both in the diagnosis and treatment of variety of malignancies. Novel epigenetic markers are being studied, which have the potential as sensitive diagnostic and prognostic markers. DNA methylation has been identified as a powerful diagnostic tool in classification, detection and risk assessment of cancers. As DNA methylation is reversible, inhibitors of DNA methyl transferases and histone deacteylases have been designed for use in treatment of a variety of urological malignancies. Variety of drugs targeting epigenetic changes are being studied, which can be effective individually or in combination with other conventional drugs used in cancer therapy. The emerging area of epigenetic therapy holds great promise for novel chemotherapeutic and chemoprevention approaches against cancer.

Original languageEnglish (US)
Pages (from-to)3535-3541
Number of pages7
JournalThe Canadian journal of urology
Volume14
Issue number3
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'The emerging role of epigenetics in urological cancers.'. Together they form a unique fingerprint.

  • Cite this

    Ramachandran, K., Soloway, M. S., Singal, R., & Manoharan, M. (2007). The emerging role of epigenetics in urological cancers. The Canadian journal of urology, 14(3), 3535-3541.